XML 260 R216.htm IDEA: XBRL DOCUMENT v3.22.4
Segment information - Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method (Details)
€ in Millions, $ in Millions
 1 Months Ended 12 Months Ended
May 29, 2020
EUR (€)
shares
Jun. 30, 2022
EUR (€)
Jun. 30, 2022
USD ($)
Dec. 31, 2022
EUR (€)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
EUR (€)
shares
Dec. 31, 2020
EUR (€)
Disclosure of operating segments [line items]              
Share of profit/(loss) from investments accounted for using the equity method       € 68   € 39 € 359
Net income attributable to non-controlling interests       113   56 [1] 36 [1],[2]
Fair value remeasurement of contingent consideration       (27)   4 (124) [3]
Restructuring costs and similar items       (1,336)   (820) (1,089) [3]
Other gains and losses, and litigation       (370)   (5) 136 [3]
Operating income       10,656   8,126 14,113 [3]
Financial expenses       (440)   (368) (388) [3]
Financial income       206   40 53 [3]
Income before tax and investments accounted for using the equity method       10,422   7,798 13,778 [3]
Other intangible assets              
Disclosure of operating segments [line items]              
Impairment of other intangible assets, net of reversals (excluding software)       (454)   € 192 330
Other intangible assets | SAR444245              
Disclosure of operating segments [line items]              
Impairment of other intangible assets, net of reversals (excluding software)       1,586      
Eloctate              
Disclosure of operating segments [line items]              
Reversal amount       2,154      
Regeneron Pharmaceuticals, INC | Immuno-oncology collaboration agreement              
Disclosure of operating segments [line items]              
Upfront payments for projects under collaboration agreements | $         $ 900    
Regular milestone payments for projects under collaboration agreements   € 96 $ 100   $ 100    
Regeneron              
Disclosure of operating segments [line items]              
Share of profit/(loss) from investments accounted for using the equity method € 343           343
Non-current financial assets, number of shares (in shares) | shares 400,000         279,766  
Regeneron | Public offering              
Disclosure of operating segments [line items]              
Sale of stock, number of shares issued in transaction (in shares) | shares 13,000,000            
Regeneron | Repurchase from the counterpart | Regeneron Pharmaceuticals, INC              
Disclosure of operating segments [line items]              
Shares agreement, sale of stock, number of shares issued in transaction (in shares) | shares 9,800,000            
Operating segments              
Disclosure of operating segments [line items]              
Business operating income       13,040   € 10,714 9,759
Material reconciling items              
Disclosure of operating segments [line items]              
Share of profit/(loss) from investments accounted for using the equity method       (88)   (39) (16)
Net income attributable to non-controlling interests       33   56 38
Amortization and impairment of intangible assets (c)       (1,599)   (1,772) (2,011)
Fair value remeasurement of contingent consideration       27   (4) 124
Expenses arising from the impact of acquisitions on inventories       (3)   (4) (53)
Restructuring costs and similar items       (1,336)   (820) (1,089)
Other gains and losses, and litigation       (370)   (5) 136
Gain on divestment of Regeneron shares on May 29, 2020       0   0 7,225
Income from out-licensing       € 952   € 0 € 0
[1] Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.
[2] (j)    Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.
[3] Includes the impacts of the IFRIC final agenda decisions of March 2021 on the costs of configuring or customising application software used in a Software as a Service (SaaS) arrangement and of April 2021 on the attribution of benefits to periods of service, as described in Note A.2.1. to the consolidated financial statements for the year ended December 31, 2021.